Explore

Companies

Drugs

About·Data Management·Terms·Privacy

Stay informed

© 2026 VivoSeq. All rights reserved.

CD4CAR

Phase 1Cell therapy

CD4CAR is one of 75 biologic programs targeting T - Cell Lymphoma. It is currently in Phase 1.

3

Indications

3

Total Trials

3

Active Trials

74

Competitors

Pipeline

Status by Indication[3][1]

Indication

T - Cell LymphomaRecruiting

Chronic Myelomonocytic LeukemiaRecruiting

Acute Myeloid LeukemiaRecruiting

T - Cell LymphomaPhase 1

Recruiting

Chronic Myelomonocytic LeukemiaPhase 1

Recruiting

Acute Myeloid LeukemiaPhase 1

Recruiting

Competition

Competitive Landscape

255 competitors in Acute Myeloid Leukemia

#DrugCompanyPhaseTrials

Idamycin

Novantrone

Xospata

Vepesid

Cerubidine

EEastern Cooperative Oncology Group

Mylotarg

WWyeth-Lederle Vaccines

Neupogen

EEastern Cooperative Oncology Group

Nexavar

Cellcept

Trexall

Jazz Pharmaceuticals

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q4 2042

Phase 1Recruiting

Acute Myeloid Leukemia

NCT06197672

Phase 1Recruiting

T - Cell Lymphoma

NCT03829540

Q4 2043

Phase 1Recruiting

Chronic Myelomonocytic Leukemia

NCT06071624

Clinical

Trials by Indication[1]

Chronic Myelomonocytic Leukemia1 trial

CD4CAR T Cell Therapy for CMML

Recruiting·HHuda Salman·Phase 1·NCT06071624·30 enrolled

Acute Myeloid Leukemia1 trial

Chimeric Antigen Receptor T Cell Redirected to Target CD4 Positive Relapsed Refractory AML as a Bridge to Allogeneic Stem Cell Transplant

Recruiting·HHuda Salman·Phase 1·NCT06197672·30 enrolled

T - Cell Lymphoma1 trial

A Phase I, Multicenter Study of CD4- Directed Chimeric Antigen Receptor Engineered T-cells (CD4CAR) in Patients With Relapsed or Refractory CD4+ Hematological Malignancies

Recruiting·HHuda Salman·Phase 1·NCT03829540·20 enrolled

Sources

References

[1]
ClinicalTrials.gov — 3 trial records for CD4CAR. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — CD4CAR compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for CD4CAR. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Huda Salman company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Cell therapy[2]
Highest Phase: Phase 1[1]
Company: HHuda Salman

Related News